ASPEN PHARMACARE HOLDINGS LIMITED - Group Financial Results for the six months ended 31 December 2021

Group Financial Results for the six months ended 31 December 2021

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa)
("Aspen Holdings")
Registration number: 1985/002935/06
Share code: APN
ISIN: ZAE000066692
LEI: 635400ZYSN1IRD5QWQ94
and its subsidiaries (collectively "Aspen" or "the Group")

GROUP FINANCIAL RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2021

SALIENT RESULTS
Aspen reported the following salient results:
- Revenue from continuing operations increased by 4% (+10% in constant exchange rate ("CER")) to R19,4 billion
  (December 2020: R18,6 billion);
- Normalised EBITDA from continuing operations increased by 10% (+15% in CER) to R5,7 billion (December 2020:
  R5,2 billion);
- Normalised headline earnings per share from continuing operations increased by 21% (+26% in CER) to 816.4 cents
  (December 2020: 676,2 cents);
- Headline earnings per share from total operations increased by 37% (+43% in CER) to 777,2 cents (December 2020:
  566,2 cents);
- Earnings per share from total operations increased by 32% (+37% in CER) to 736,2 cents (December 2020: 558,4 cents); and
- Aspen secures right to branded COVID-19 vaccine Aspenovax.

REGULATORY REQUIREMENTS

The contents of the short form announcement are the responsibility of the Board of directors of Aspen. The
information in the short form announcement is a summary of the full announcement available on the Company's website at
https://www.aspenpharma.com/investor-information/ on 9 March 2022 and accordingly does not contain full or complete
details. The full announcement can also be accessed online at
https://senspdf.jse.co.za/documents/2022/jse/isse/APN/HYresults.pdf

The information in this announcement has been extracted from the unaudited interim financial results for the six months
ended 31 December 2021, but the short-form announcement itself has not been reviewed by the Company's auditors. The
unaudited interim financial results have been prepared under the supervision of the Group Chief Financial Officer,
Sean Capazorio, CA(SA).

Any investment decisions by shareholders/investors should be based on the full announcement as released by the JSE and
published on the Company's website, https://www.aspenpharma.com. The full announcement is also available at the
Company's registered office (for inspection, at no charge, during office hours on any business day) and at the offices
of the sponsor, Investec Bank Limited, from 10 March 2022 to 31 March 2022, both days inclusive. Copies of the full
announcement may be requested by contacting Riaan Verster on telephone: +27(0)31 580 8624, email:
rverster@aspenpharma.com.

For and on behalf of the Board

Kuseni Dlamini                        Stephen Saad
Chairman Group                        Group Chief Executive

Registered office: Building 8, Healthcare Park, Woodlands Drive, Woodmead, Sandton

Woodmead
9 March 2022
Sponsor: Investec Bank Limited

Date: 09-03-2022 02:19:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.